3 February 2021 in Science Translational Medicine
Tumor lineage plasticity is emerging as a critical mechanism of therapeutic resistance and tumor relapse. Highly plastic tumor cells can undergo phenotypic switching to a drug-tolerant state to avoid drug toxicity. Here, we investigate the transmembrane tight junction protein Claudin6 (CLDN6) as a therapeutic target related to lineage plasticity for hepatocellular carcinoma (HCC). CLDN6 was highly expressed in embryonic stem cells but markedly decreased in normal tissues. Reactivation of CLDN6 was frequently observed in HCC tumor tissues as well as in premalignant lesions. Functional assays indicated that CLDN6 is not only a tumor-associated antigen but also conferred strong oncogenic effects in HCC. Overexpression of CLDN6 induced phenotypic shift of HCC cells from hepatic lineage to biliary lineage, which was more refractory to sorafenib treatment. The enhanced tumor lineage plasticity and cellular identity change were potentially induced by the CLDN6/TJP2 (tight junction protein 2)/YAP1 (Yes-associated protein 1) interacting axis and further activation of the Hippo signaling pathway. A de novo anti-CLDN6 monoclonal antibody conjugated with cytotoxic agent (Mertansine) DM1 (CLDN6-DM1) was developed. Preclinical data on both HCC cell lines and primary tumors showed the potent antitumor efficiency of CLDN6-DM1 as a single agent or in combination with sorafenib in HCC treatment.
18 March 2026 in Ecotoxicology and Environmental Safety
Environmental plasticizers are increasingly implicated in asthma susceptibility, yet the mechanisms linking chemical exposure to airway inflammation remain poorly defined. Here we show that the plasticizer di(2-ethylhexyl) phthalate (DEHP) directly drives a neutrophil-dominant asthma phenotype through activation of IL-17-centered immune pathways. Integrative network toxicology identified IL-6 and IL-1β as central inflammatory nodes connecting DEHP exposure with Th17 differentiation and IL-17 signaling. Consistent with these predictions, inhalational DEHP exposure in mice induced airway hyperresponsiveness, mixed granulocytic airway inflammation, mucus hypersecretion, and elevated pulmonary IL-6, IL-1β, and IL-17A expression. Immune profiling revealed expansion of IL-17A-producing lymphocytes, including Th17 cells and type 3 innate lymphoid cells (ILC3s). Genetic ablation of IL-17A markedly attenuated airway hyperresponsiveness and neutrophilic inflammation following DEHP exposure. Together, these findings identify an IL-6/IL-1β-Linked Th17/ILC3 axis as a mechanistic link between environmental plasticizer exposure and non-type 2 asthma, providing a conceptual framework for pollutant-driven airway disease.
9 March 2026 in Research Square
Steroid-resistant asthma (SRA) driven by airway infection and neutrophilic inflam-mation remains poorly treatable with glucocorticoids (GCs). Using a recombinant Pseudomonas aeruginosa exotoxin A (rPEA)-induced mouse model, we reveal MALT1 as an upstream regulator of GC resistance. rPEA triggered neutrophilic in-flammation, hyperresponsiveness, and remodeling unresponsive to GCs, alongside suppressed glucocorticoid receptor (GR) and histone deacetylase 2 (HDAC2) activity. MALT1 activation induced macrophage migration inhibitory factor (MIF), which enhanced IL-21 and IL-17A–dependent inflammation. Disrupting IL-21/IL-21R or IL-17A signaling partially restored GC sensitivity. Inhibiting MALT1 or MIF reduced inflammation and reactivated GR/HDAC2 signaling. Combining MALT1/MIF inhi-bition with dexamethasone synergistically ameliorated airway disease. Our results establish MALT1 as a key mediator of steroid resistance via the MIF–IL-21–IL-17 axis, offering a therapeutic strategy to restore GC responsiveness in infection-related SRA.